Belinda Cancilla

Amgen (United States) — United States

Medicine · Health Sciences

20h-index3.7kcitations73works5.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(12), Cancer, Hypoxia, and Metabolism(11), Cancer-related gene regulation(11), Fibroblast Growth Factor Research(7), Developmental Biology and Gene Regulation(6)

Publications73 total

NLRP10 maintains epidermal homeostasis by promoting keratinocyte survival and P63-dependent differentiation and barrier function
Cell Death and Disease·2024· 5 citedOpen Access
Supplementary Tables 1 - 3, Figure 1 from Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
2023Open Access
Supplementary Tables 1 - 3, Figure 1 from Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
2023Open Access
Data from Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
2023Open Access
Data from Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
2023· 1 citedOpen Access
Supplementary Figures 1-8 from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Supplementary Tables 1-5, Supplementary Methods and Materials from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Data from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Data from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Supplementary Figures 1-8 from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Supplementary Tables 1-5, Supplementary Methods and Materials from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Figures S1-S7 from Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types
2023Open Access
Data from Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types
2023Open Access
Tables S1-S3 from Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types
2023Open Access
Legends for Figures S1-S7 from Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types
2023Open Access
Tables S1-S3 from Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types
2023Open Access
Figures S1-S7 from Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types
2023Open Access
Data from Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types
2023Open Access
Legends for Figures S1-S7 from Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types
2023Open Access
Abstract 3826: GITRL-Fc biomarker and mechanism study: GITRL-Fc reduces Treg frequency in tumors and requires effector function for inhibition of tumor growth
Cancer Research·2018
page 1 of 4Next →

Frequent Co-authors

Ann M. Kapoun(26), John Lewicki(25), Austin Gurney(22), Marcus Fischer(18), Wan-Ching Yen(18), Timothy Hoey(16), Pete Yeung(14), Gilbert O’Young(12), Jennifer Cain(11), Fumiko Axelrod(10), Jalpa Shah(10), Tim Hoey(10), Fiore Cattaruzza(9), Tracy Tang(8), Gail P. Risbridger(8), Felix Chu(7), Chun Zhang(7), Peiwen Yu(6), Frauke Bentzien(6), Raymond Tam(6)